Company profile
TAYSHA GENE THERAPIES, INC.
NASDAQ:TSHABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LONIMECGENE RENPARVOVEC | phase3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05606614 | phase3 | active_not_recruiting | 2023-03-06 | 2031-06-01 | Taysha Gene Therapies, Inc. | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) |
| NCT06152237 | phase1_2 | active_not_recruiting | 2023-12-12 | 2028-11-02 | Taysha Gene Therapies, Inc. | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) |
| NCT07480564 | phase3 | active_not_recruiting | 2026-05-08 | 2031-06-01 | Taysha Gene Therapies, Inc. | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome |
FDA applications (0)
No records yet.